← Fulgent Genetics, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $18.3m $18.7m $21.4m $32.5m $421.7m $992.6m $619.0m $289.2m $283.5m $322.7m
Cost of Revenue $6.7m $8.6m $0 $0 $89.8m $215.5m $252.1m $184.8m $176.3m $191.8m
Gross Profit $11.6m $10.2m $10.7m $18.4m $331.9m $777.1m $366.9m $104.5m $107.2m $130.9m
Operating Expenses $10.6m $13.7m $15.7m $18.8m $41.7m $101.1m $188.4m $300.0m $181.1m $222.0m
Operating Income (Loss) $918k ($3.5m) ($5.1m) ($428k) $290.2m $676.0m $178.5m ($195.5m) ($73.9m) ($91.1m)
Additional Financial Items
Amortization of Intangible Assets — — — — — $1.7m $6.5m $7.8m $8.0m $8.0m
Goodwill, Impairment Loss — — — — — — $0 $120.2m $0 $0
Income (Loss) from Continuing Operations before Income Taxes, Domestic $4.5m — — $679k $291.7m $681.4m $189.4m ($147.5m) ($46.8m) ($61.8m)
Income (Loss) from Continuing Operations, Per Basic Share — — ($0) ($0) $9 $17 $5 ($6) ($1) ($2)
Income (Loss) from Continuing Operations, Per Diluted Share — — ($0) ($0) $9 $16 $5 ($6) ($1) ($2)
Income (Loss) from Equity Method Investments — ($524k) ($935k) ($777k) ($488k) — — — — —
Interest and Other Income — — — $837k $1.5m $1.3m $5.5m $21.4m — —
Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss — — — — — — — — ($994k) $62k
Operating Lease, Lease Income — — — — $145k $420k $281k $164k — —
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($4.5m) — — $409k $291.7m $677.3m $184.0m ($174.1m) ($52.0m) ($70.0m)
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($5.4m) ($2.5m) — — — — — — — —
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $41k — — — — — — — — —
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $41k $0 — — — — — — — —
Net Income (Loss) Attributable to Parent ($5.3m) ($2.5m) ($5.6m) ($411k) $214.3m $507.4m $143.4m ($167.8m) ($42.7m) ($60.5m)
Net Income (Loss) Available to Common Stockholders, Basic ($13.7m) ($2.5m) — — — — — ($167.8m) ($42.7m) ($60.5m)
Net Income (Loss) Attributable to Noncontrolling Interest — — — — — ($1.1m) ($1.5m) ($7.4m) ($1.1m) ($1.1m)
Weighted Average Number of Shares Outstanding, Basic — — 18.0m 18.7m 22.7m 29.4m 30.1m 29.8m 30.2m 30.8m
Weighted Average Number of Shares Outstanding, Diluted — — 18.0m 18.7m 24.1m 31.0m 31.0m 29.8m 30.2m 30.8m
Research and Development Expense $3.6m $4.2m $5.5m $6.5m $11.6m $24.2m $28.9m $41.4m $48.8m $53.9m
General and Administrative Expense $4.6m $5.2m $5.5m $6.4m $15.2m $50.7m $111.1m $89.0m $88.1m $116.7m
Other Nonoperating Income (Expense) — — — — — — — — $561k $153k
Interest Expense (non-operating) — — — — — — — — ($170k) $75k
Current Income Tax Expense (Benefit) $674k ($679k) $0 $43k $74.3m $183.0m $50.4m ($10.3m) ($4.4m) ($7.3m)
Interest Expense — — — — $20k $117k $346k $488k $170k $75k
Restructuring Costs — — — — — — $3.0m $0 $0 —
Selling and Marketing Expense $2.5m $4.2m $4.7m $5.9m $15.0m $24.4m $38.9m $41.5m $36.2m $43.4m
Income Tax Expense (Benefit) $920k ($1.0m) $36k $43k $72.5m $174.8m $42.1m $1.2m ($8.1m) ($8.4m)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.